InterBioScreen (IBS), global provider of unique chemical compound libraries, and Quantum Pharmaceuticals, high-tech drug discovery company, announced a new project to create a revolutionary product for the drug discovery market.
The joint project, QuantumLead, combines the industry leading in silico lead optimization technology of Quantum Pharmaceuticals with the unique synthetic and natural compound libraries and network of scientists of IBS to create Q-Lead-Libraries.
Q-Lead-Libraries are libraries of compounds, which are ranked according to their constant affinity to particular protein targets. They are designed to allow biotech and pharmaceutical companies to achieve a dramatic acceleration of the drug discovery R&D process by reducing or eliminating the time involved in screening and optimization of hits and leads. Using Q-Lead Libraries will enable biotech and pharmaceuticals companies to find exclusive novel drug candidates more quickly and at a lower cost.
The technology behind Q-Lead-Libraries™ is Quantum Pharmaceuticals’ proprietary intermolecular modeling tools and accurate affinity calculations. The technology provides for full flexibility of both ligands and proteins and takes into account all factors of binding free energy including solvation effects, Van Der Waals energy in solution, as well as electrostatic and entropy contribution.
The joint in-house drug development program is expected to produce a broad range of novel drug candidates for HIV-1 integrase (AIDS), hsp90 (oncology) and beta-secretase (Alzheimer’s Disease) that will be marketed and out-licensed by both companies at the preclinical stage.
About Quantum Pharmaceuticals: Quantum Pharmaceuticals is a Moscow-based biotech company, which has created and continues to develop computational drug discovery technology that is breaking the limits of computational simulation of molecular interactions.
About InterBioScreen: InterBioScreen is one of the largest global providers of high quality chemical libraries for pharmaceutical, biotech and agricultural companies. InterBioScreen carries out targeted synthesis of new chemical drug-like compounds which cannot be synthesized by combinatorial methods, including new and unusual classes of organic compounds.
Courtney Ranson | Source: Quantum Pharmaceuticals
Further information: www.q-pharm.com
www.ibscreen.com
More articles from
Health and Medicine:
Does hormone treatment predispose patients to breast cancer?
21.11.2008 | CNRS (Délégation Paris Michel-Ange)
Mechanisms of cardiovascular disease and cancer give clues to new therapies
21.11.2008 | European Science Foundation
Sustainable garden roofs developed as a new construction material
21.11.2008 | Studies and Analyses
Bees declared the winners in Earthwatch’s ‘irreplaceable species’ battle
21.11.2008 | Ecology, The Environment and Conservation
Hairspray is linked to common genital birth defect
21.11.2008 | Studies and Analyses
The Automobile – The Transition from Energy Guzzler to Power Supplier
20.11.2008 | Event News
Ministers meet to define the role of space in delivering global objectives
18.11.2008 | Event News
156th Annual Acoustical Society of America (ASA) Meeting in Miami
28.10.2008 | Event News